Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.65 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.65 |
| ▸ | DRD3 | P35462 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prodilidine SCHEMBL120377 | 0.99 | LMNA (0.72) | LMNAOPRM1OPRD1OPRK1DRD3 | |
| Betaprodine SCHEMBL186644 | 0.83 | LMNA (0.97) | LMNAOPRM1OPRD1OPRK1DRD3 | |
| Alphaprodine SCHEMBL25054 | 0.83 | LMNA (0.97) | LMNAOPRM1OPRD1OPRK1DRD3 | |
| Betaprodine SCHEMBL25053 | 0.83 | LMNA (0.97) | LMNAOPRM1OPRD1OPRK1DRD3 | |
| Betaprodine SCHEMBL248367 | 0.83 | LMNA (0.97) | LMNAOPRM1OPRD1OPRK1DRD3 | |
| Alphaprodine SCHEMBL8818643 | 0.82 | LMNA (1.00) | LMNAOPRM1OPRD1OPRK1DRD3 | |
| Betaprodine SCHEMBL394431 | 0.82 | LMNA (1.00) | LMNAOPRM1OPRD1OPRK1DRD3 | |
| Betaprodine SCHEMBL1649307 | 0.81 | LMNA (0.93) | LMNAOPRM1OPRD1OPRK1DRD3 | |
| SCHEMBL11383571 | 0.80 | LMNA (0.78) | LMNAOPRM1OPRD1OPRK1DRD3 | |
| Trimeperidine SCHEMBL1649689 | 0.79 | OPRM1 (0.76) | LMNAOPRM1OPRD1OPRK1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 925 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200345722-A1 | ABUSE-DETERRENT DRUG FORMULATIONS | COLLEGIUM PHARMACEUTICAL INC (US) | 2020-11-05 | — | — | US | claimed |
| US-20200345723-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS | COLLEGIUM PHARMACEUTICAL INC (US) | 2020-11-05 | — | — | US | claimed |
| US-20200093820-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2020-03-26 | — | — | US | claimed |
| US-20200093819-A1 | ABUSE-DETERRENT DRUG FORMULATIONS | COLLEGIUM PHARMACEUTICAL, INC. | 2020-03-26 | — | — | US | claimed |
| EP-3326617-A1 | ABUSE-DETERRENT DRUG FORMULATIONS | Collegium Pharmaceutical, Inc. (US) | 2018-05-30 | — | — | EP | claimed |
| US-20180028529-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS | COLLEGIUM PHARMACEUTICAL, INC. | 2018-02-01 | — | — | US | claimed |
| US-20180028528-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS | COLLEGIUM PHARMACEUTICAL, INC. | 2018-02-01 | — | — | US | claimed |
| US-20170360710-A1 | ABUSE-DETERRENT DRUG FORMULATIONS | COLLEGIUM PHARMACEUTICAL, INC. | 2017-12-21 | — | — | US | claimed |
| US-20150265596-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS | COLLEGIUM PHARMACEUTICAL, INC | 2015-09-24 | — | — | US | claimed |
| US-9044398-B2 | Abuse-deterrent pharmaceutical compositions of opiods and other drugs | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2015-06-02 | — | — | US | claimed |
| EP-1594467-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS | Collegium Pharmaceutical, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| EP-1551370-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2005-07-13 | — | — | EP | claimed |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2004-06-03 | — | — | US | claimed |
| WO-2004032900-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2004-04-22 | — | — | WO | claimed |
| US-20040052731-A1 | Abuse-deterrent pharmaceutical compositions of opiods and other drugs | COLLEGIUM PHARMACEUTICALS, INC. | 2004-03-18 | — | — | US | claimed |
| WO-2004004693-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIODS AND OTHER DRUGS | COLLGEGIUM PHARMACEUTICAL (US) | 2004-01-15 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | LMNA 891/4885OPRM1 1959/4885OPRD1 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.